吉利德将以78亿美元收购细胞疗法合作伙伴Arcellx。
Gilead to acquire cell therapy partner Arcellx for $7.8B
生物技术与制药领域的最新动态
Gilead to acquire cell therapy partner Arcellx for $7.8B
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
MoonLake has 'confidence' ahead of FDA submission, discloses mid-stage arthritis win
Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more
Vanda gets FDA approval for ‘franchise-extending’ antipsychotic
Grail's cancer test faces new uncertainty after UK study
Ionis scraps Alzheimer’s drug for people with Down syndrome
Supreme Court tariff ruling lets stand Trump’s authority to target pharma
Candel prices offering, signs royalty deal; Calquence label expands
Daiichi taps John Tsai to lead R&D as Ken Takeshita departs
Novartis to divest India unit to private equity-led consortium for $159M
Sanofi appoints specialty care head; Biogen chair to retire in June
Grail's cancer test misses primary study goal in UK study
AbbVie, PhRMA can proceed with 340B case in Hawaii
When a health tech startup gets stuck in regulatory limbo
Teva beats Corcept in appeals fight over generic Cushing's syndrome drug
FDA formalizes one pivotal trial policy via NEJM perspective
Obesity biotech Verdiva plans big year of data, explores deals
Biogen stops part of an MS trial; Merck reports more Enflonsia data
Sanofi to expand in India; Stada invests $100M in Saudi Arabia